deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT00556127

Rituximab in Addition to Chemotherapy With Autologous Stem Cell Transplantation as Treatment Diffuse Large B-Cell Lymphoma (DLBCL)

Programma di Terapia Per Pazienti Affetti da Linfoma Diffuso a Grandi Cellule B CD20 Positive

Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

Conditions Diffuse Large B-Cell Lymphoma POOR PROGNOSIS
Interventions Carmustine BCNU Cyclophosphamide Cytarabine ARA-C Dexamethasone Epirubicin Etoposide Granulocyte-colony-stimulating factor Melphalan Mitoxantrone PBSC reinfusion Prednisone Radiotherapy Rituximab Vincristine
Updated 4 times since 2017 Last updated: Nov 8, 2007 Started: Jun 30, 2002 Completion: Sep 30, 2006
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00556127, this PHASE2 trial focuses on Diffuse Large B-Cell Lymphoma and POOR PROGNOSIS and remains completed. Sponsored by Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie, it has been updated 4 times since 2002, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Jan 2021 · 48 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

4 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2017 — Jan 2021 [monthly]

    Completed PHASE2

    First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Data source: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations